Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anavex Life Sciences has reported that Anavex 7-1037 demonstrated its ability to kill human HCT116 colon cancer cells and significantly suppress tumor growth in immune-deficient mice in advanced pre-clinical studies.
Subscribe to our email newsletter
Ongoing pre-clinical studies are being conducted in collaboration with Universite Montpellier in France. These studies on immune-deficient mice are designed to assess and analyze Anavex 7-1037’s ability to slow down and prevent tumor growth, stop cancer cells from spreading, enable the growth of new blood vessels and increase the number of cells through cell growth and division.
Pre-clinical studies so far suggest that Anavex 7-1037, the company’s lead drug candidate for the treatment of colorectal cancer and other types of solid tumors, may possess chemotherapeutic potential for the treatment of colorectal and other types of human cancer.
Dr Kontzalis, CEO of Anavex, said: “These results are very encouraging, particularly regarding the therapeutic signals from the significant in vivo anti-cancer activity against HCT116 xenografts at low nanomolar level.”